SEARCH

Arvind Vasudeva is new CEO of Aurobindo Pharma

Our Bureau
Comment   ·   print   ·  
Arvind Vasudeva
BL Arvind Vasudeva

Aurobindo Pharma Ltd has appointed Arvind Vasudeva as Chief Executive Officer for its formulations division.

The Hyderabad-based pharma major in an announcement to the stock exchanges said his appointment will be effective from November 22.

Arvind Vasudeva served as Chief Operating Officer at Glenmark Pharmaceuticals prior to joining Aurobindo Pharma. He was instrumental in the growth of the company there. He also worked as the Managing Director of RPG Life Sciences Ltd. In addition, he also was President-Indian operations as well as Japan and ROW markets in Wockhardt.

Arvind, an M. Pharm (Pharmaceutical Technology) from Punjab University, Chandigarh, has three decades of experience in the formulations sales and marketing. “His expertise, professional capabilities and leadership will help the company strengthen its position in the pharma space further,” said K. Nithyananda Reddy, Vice-Chairman, Aurobindo Pharma, in a statement.

Incidentally, on November 9, the company had accepted the resignation of Ravindra Y. Shenoy, Joint Managing Director, who resigned due to personal reasons. N. Govindrajan is the Managing Director at present.

Meanwhile, the company’s scrip lost Rs 2.25 or 1.26 per cent on the bourses to close at Rs 176.40.

Somasekhar.m@thehindu.co.in

(This article was published on November 23, 2012)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.

Comments:

This article is closed for comments.
Please Email the Editor

DATA BANK

Exchange Rate

Dollar Spot Forward Rate


O
P
E
N

close

Recent Article in Companies

Eveready Q3 soars to ₹15.33 cr

Eveready Industries Ltd has reported 238 per cent jump in net profit at ₹15.33 crore in the third quarter ending December 31, 20... »

Comments to: web.businessline@thehindu.co.in. Copyright © 2015, The Hindu Business Line.